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Abstract
In the nineteenth century, researchers discovered that some proteins had the ability to
agglutinate red blood cells (Goldstein, 1980). These proteins were found mainly in the seeds of
leguminous plants and were named phytohemagglutinins or hemagglutinins. Particular
hemagglutinins were able to agglutinate red blood cells (RBCs) of a specific blood type. Now a
days, these proteins are more widely known as Lectins. Lectins are proteinaceous
macromolecules of nonimmune origin, capable of interacting with carbohydrates to form
complexes (Goldstein, 1980). Lectins sources derive mainly from leguminous plants, animals,
fruiting bodies of fungi, and bacteria. This research focuses on identifying the lectin activity and
characteristics of certain synthetic compounds. Lectin activity was assessed by
observing agglutination reactions of synthetic compounds and human red blood cells of a
known human blood group and type in the ABO system. Lectins continue to be the focus of
research due to their potential diverse applications specifically for blood grouping, mitogenic
activity, and even stem cell transplantation.
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Introduction
Lectins are proteinaceous macromolecules of nonimmune origin, capable of interacting
with carbohydrates to form complexes (Goldstein, 1980). Lectins are derived from a variety of
sources. They are widely seen in seeds of leguminous plants, animals, fruiting bodies of fungi,
and bacteria.
In the 19 century, researchers discovered the ability of some proteins to agglutinate red
th

blood cells (Goldstein, 1980). These proteins, mainly found in the seeds of leguminous plants,
were named phytohemagglutinins or hemagglutinins (Gorakshakar, & Ghosh, 2016). Later,
particular hemagglutinins were found to agglutinate red blood cells (RBC’s) of a particular
human blood type in the ABO blood group system. As a result, in 1954, Boyd and Shapleigh
named these hemagglutinins “lectins” from the Latin word legere, meaning “to choose” or “to
select” (Goldstein, 1980).
In 1888, Peter Hermann Stillmark isolated toxic extracts from seeds of the castor tree,
Ricinus communis, and found that these hemagglutinating proteins agglutinated human
erythrocytes and named them “ricin” (Lis & Sharon, 2004). Similarly, in 1891, as the 19th
century sparked collaborative efforts for early research in protein agglutinating activity, H.
Hellin isolated abrin, toxic protein obtained from the seeds of the jequirity bean, Abrus
precatorius, which is similar in structure and properties to ricin (Dickers, Bradberry, Rice,
Griffiths, & Vale, 2003). However, it was not until 1919, that Sumner isolated extracts from jack
bean seeds (Canavalia ensiformis), purified it for the first time, and named it concanavalin A
(Goldstein, 1980).
Further research into the agglutinating properties of lectins quickly ensued with a
particular focus on research aimed at identifying new lectin sources. In 1940, William Boyd and
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Karl Renkonen discovered that extracts of lima bean, Phaseolus limensis, agglutinated type A
human red cells but not type B or type O (Lis & Sharon, 2004). In 1959, G. W. G. Bird reported
that precipitins from Dolichos biflorus seeds reacted with part of the A‐substance of human red
blood cells; specifically, an A-substance component found in individuals with sub‐groups A
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(Bird, 1959; Etzler & Kabat, 1970). Extracts from the asparagus pea, agglutinated type O human
red cells but no other red cell types (Sharon & Lis, 2004).
Lectins continue to be the focus of research due to their potential and diverse applications
specifically for blood grouping, mitogenic activity, challenges related to polyagglutination, and
stem cell transplantation (Hammid, Masood, & Rafiq, 2013). There has been great effort in
characterizing legume-derived lectins (Hamid, Masood, Wani, & Rafiq, 2013; Lagarda-Diaz,
Guzman-Partida, Vazquez-Moreno, 2017) and their positive and negative health effects. The
study of lectins remains a prolific field with novel lectins becoming the focus of recent studies (e
Lacerda et al., 2017; Torres et al, 2019).
Specific applications of lectins hinge on meticulous characterization of their properties
and the identification of carbohydrate-specific binding sites. This research will focus on
determining lectin properties of synthetically produced Glucuronate, Alginate, and related
Boronates and aims to categorize the compounds according to their lectin-characteristic
structures followed by their selective interaction with human red cells. These compounds have
been previously screened for Lectin properties; however, specificity was within the scope of that
previous study (Koshar, 2018).
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Methodology
Background
The agglutination of human red blood cells will be used as an indication of lectin activity.
Agglutination is a standard serological method in the clinical laboratory to detect antibodyantigen interactions through visible clumping or agglutination.
In immunohematology, commonly known as blood banking, determinations of antigen
and antibodies are the key to identifying blood groups, unexpected antibodies, and making sure
blood compatibility is achieved. Antibodies are glycoproteins capable of recognizing a specific
antigen. Antibodies concerning the blood bank are present in the serum and plasma. In contrast,
antigens relevant to immunohematology are found on the cell membrane of red blood cells.
Hemagglutination occurs when an antigen binds with a corresponding antibody. In the blood
bank, hemagglutination is graded on basis of 4+, 3+, 2+, 1+, Negative. A 4+ is a visible red cell
solid agglutinate with a clear background. A 3+ are several large red agglutinates with a clear
background. A 2+ are may medium-sized agglutinins with a clear background. A 1+ are many
medium and small sized agglutinates with a reddish turbish background. Negative is the absence
of agglutination.
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Figure 1. This figure shows the agglutination reactions from 4+ to a negative (0). A positive reaction raises awareness that there
is significance and the laboratorian should be alert.

While previous research indicates that red cell agglutination has been observed with
certain synthetically derived compounds, studies on specificity were not conducted (Koshar,
2018). Therefore, the focus of this study was to first confirm previous findings reported on initial
testing as reported by Koshar (2018), followed by specificity testing.
Testing Protocol
Type A, B, and O human red blood cells, from voluntarily donated units were used and
five compounds were donated by the Andrews Chemistry department and Dr. Murray. Donated
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blood is collected in bags containing acid citrate dextrose (ACD)-A, which contains 3% citrate to
prevent coagulation and maximize cell life. Red cells for testing are prepared by washing the
cells 3-4 times with 0.85% NaCl (isotonic saline). The washed red cells were then used to
prepare a 2-5% red cell suspension in saline. The 2-5% red cell suspension was prepared as
follows: To a labeled tube, I added 1 mL of whole blood. After I added the blood, I washed cells
in saline for 5 minutes four times, removed last aspiration, and kept the pellet. Next, I added .3
mL of washed cells to another tube with 9.7 mL of saline. After adding washed cells with saline,
I capped the tube with parafilm and shook it to obtain 2-3% red cell suspension or centrifuge for
15 seconds a total of 3-4 times. Finally, I added enough saline to achieve an adequate 2-5% red
cell suspension.
A stock solution for each compound was prepared by adding 0.02 grams of each of the
synthetically produced compounds to 1 mL of DMSO. The solution was mixed until dissolved.
Testing for hemagglutination was performed as follows:
1. Label 6 test tubes with respective compounds.
2. Add one drop of compound (ID) stock solution to each test tube.
3. Add 1 drop of 2-5% human red blood cell suspensions (refer to procedure for
preparing a 2-5% red cell suspension)
4. Centrifuge for 15 seconds.
5. Examine tubes both macroscopically and microscopically for the presence of
agglutination.
The tubes were examined macroscopically through grading of the tube using the standard
grading method procedure on a scale of 4+-0. Additionally, I examined the tubes microscopically
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through looking for clumping of cells with the aid of a microscope. Agglutination was observed
through agglutination of cells, or clumping of cells.
Preparation of Controls
Controls for each stock solution were also prepared. However, initially there were some
challenges in obtaining a suitable control. This had to do with DMSO, the solvent, causing the
red cells to agglutinate. This reaction was unexpected because in previous studies (Koshar, 2018)
this was not mentioned. To remediate this problem, a negative control was obtained by adding a
1:2 dilution of saline with DMSO as the control. It was necessary to have the DMSO and red cell
suspension show no agglutination. This would allow the researcher to attribute any degree of
agglutination to the compound and not the solvent. A negative control was achieved by diluting
the DMSO with 0.85% NaCl.
A negative control was obtained with added compound and .5 ml of saline and .5 ml of
DMSO. Additionally, a negative was also obtained with added compound and .5 ml of DMSO
and .25 ml of saline. Thus, a negative control of .5 ml of DMSO and .25 ml of saline was used.
Additionally, a prewarming technique was used in this experiment. First, the stock solution was
heated at 37 degrees for 10 minutes as well as heating up each of the blood types. After heating
up the stock solution and blood types, one drop of type A, B and O positive cells were placed in
single tubes with stock solutions. At the end of the ten minutes, the tubes were centrifuged and
read to record the results. The tubes were also read microscopically and macroscpically.

Results
Five synthetically produced compounds were used in this experiment: three glucuronic
acid boronates and two acetylneuraminic acid boronates. The five compounds tested were 4-
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bromomethyl phenyl boronic acid and glucuronic acid, 2-bromomethyl phenyl boronic acid and
glucuronic acid, 3-bromomethyl phenyl boronic acid and glucuronic acid, 2-bromomethyl phenyl
boronic acid and acetylneuraminic acid, and 3-bromomethyl phenyl boronic acid and
acetylneuraminic acid. Solubility proved to be a problem; therefore, only two compounds were
ultimately tested for lectin properties through agglutination. Solubility was a problem because
only 2 compounds out of five were tested. Three compounds didn’t dissolve originally with the
DMSO and thus were not used in the experiment.
The two semi-soluble compounds were 4-bromomethyl phenyl boronic acid and
glucuronic acid (compound 1) and 2-bromomethyl phenyl boronic acid and acetylneuraminic
acid (compound 6). These two compounds were tested with type A Rh positive, type B Rh
positive, and type O Rh positive human red blood cells to determine their hemagglutinin
characteristics. Neither compound showed macroscopic agglutination. Compound 1 did not show
microscopic agglutination for any of the red cell types. In contrast, compound 6 did show some
microscopic reactions. When tested with A cells (Figure 2), no microscopic agglutination was
observed. The results were similar with O cells (figure 4). However, when tested with B positive
cells, a few microscopic clumps were observed (Figure 3).

Compound Name

Compound
number

Used in the
experiment

4-bromomethyl phenyl boronic acid and glucuronic
acid

Compound 1

Yes

3-bromomethyl phenyl boronic acid and glucuronic
acid

Compound 2

No
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2-bromomethyl phenyl boronic acid and glucuronic
acid

Compound 3

No

3-bromomethyl phenyl boronic acid and
acetylneuraminic acid

Compound 4

No

2-bromomethyl phenyl boronic acid and
acetylneuraminic acid

Compound 6

Yes

Figure 2. The above synthetic compounds describe the compounds that were used and not used in this research. In total, five
compounds were donated by the chemistry department, but only two were used in the research because only two compounds
were soluble enough to be tested.

Controls consisted of 0.5 mL of DMSO and 0.5 mL of normal saline along with each of
three red blood cell types. All controls were negative for agglutination suggesting that any
agglutination observed in the solution with the compound would be attributed to the compound.

Figure 3. This figure shows
compound 6 with A positive cells.
There is no visible agglutination.

Figure 4. This figure shows
compound 6 with B positive cells.
There is slight agglutination in
comparison with other cells.

Figure 5. This figure shows
compound 6 with O positive cells.
Similar to type A cells, there is no
visible agglutination.
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Discussion
Five compounds were used in this experiment. However, solubility was a problem and only
two compounds were successfully dissolved and thus used in this experiment. The two
compounds were 4-bromomethyl phenyl boronic acid and glucuronic acid (compound 1) and 2bromomethyl phenyl boronic acid and acetylneuraminic acid (compound 6). Compound 1
showed no hemagglutinin characteristics demonstrated by the lack agglutination with all three
red cell blood types.
Although compound 6 did not show any agglutination with respect to macroscopic
observations, compound 6 did show some microscopic observation. While there was no visible
agglutination with A or O positive cells, compound 6 did show some slight hemagglutination
with B positive cells. Compound 6 demonstrated some microscopic agglutination with group B
Rh positive human red cells (figure 3). The agglutination was visible through some small clumps
throughout the fields. For example, the pointer demonstrates a small visible clump of red blood
cells after testing the red cells with 2-bromomethyl phenyl boronic acid and acetylneuraminic
acid. These results suggest some selective hemagglutinin or lectin activity for compound 6.
The research purpose was to determine and analyze lectin properties in synthetically
produced compounds. Lectins are used in the lab to help in ABO typing. The research showed
that 2-bromomethyl phenyl boronic acid and acetylneuraminic acid showed slight agglutination
with B positive red cells. This may mean that the compound could potentially be used as a lectin
source in the laboratory for ABO typing.
This research did have some limitations and strengths. For example, one weakness that I
had during this research was that I couldn’t test all the compounds because of solubility. Out of
five compounds that were donated from the chemistry department and Dr. Murray, only two
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compounds were tested. Further, the two compounds were semi-soluble. Additionally, it took
awhile to find a good control for the testing. When the tubes were first tested with DMSO and
red cells, the tubes agglutinated. Thus, a good control had to be sought in order to have validity
in the actual testing.
Despite having some limitations in this research, there were also some strengths. For
example, one strength was that a negative control was derived with a saline and DMSO ratio.
The control included in this research was .5 ml of DMSO and .25 mL of saline. Additionally,
another strength in this research was testing the two compounds with the red blood cells. Despite
having some weaknesses and strengths, there was definitely potential for further research.
Further research could include testing compound 6 lectin activity on Rh negative red
cells. This research focused on testing the compounds with A, B, and O positive cells. As a
result, testing the same compounds with Rh negative red blood cells can indicate whether or not
the compound is specific for Rh positive, Rh negative, or both. Additionally, because solubility
was a challenge, it would be good to explore other types of organic solvents.
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